Recent developments in research
- New FDA approval for EGFR exon 19 and exon 21 L858R
- LCRF Joins Lung Cancer Advocacy Organizations and 23andMe to Launch Lung Cancer Genetics Study to Advance Research
- Science Update | summer 2024
- CROWN trial findings presented at ASCO
- News from the ASCO Annual Meeting
- Accelerated approval for SCLC treatment
- LCRF expands Research Advocates group
- FDA approves alectinib for ALK+ NSCLC
- Tepotinib approved for MET exon 14
Recent FDA approvals
- New FDA approval for EGFR exon 19 and exon 21 L858R
- FDA approves alectinib for ALK+ NSCLC
- Recent FDA approval of combined therapy for initial treatment of EGFR-mutated NSCLC
- FDA approves repotrectinib for patients with advanced ROS-1 fusion non-small cell lung cancer
- FDA grants accelerated approval to adagrasib for KRAS G12C-mutated NSCLC
- FDA approves Imjudo with Imfinzi and chemo